Publications scientifiques SARS-CoV-2 / Covid-19

Liste des publications scientifiques de l’Institut Pasteur relatives au coronavirus SARS-CoV-2 et à la maladie Covid-19.

TitreAuteurDateSourcePublication
The effect of COVID certificates on vaccine uptake, health outcomes, and the economyOliu-Barton M. et al.2022Nature Communications
13 (1), 3942
10.1038/s41467-022-31394-1
Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screenMac Kain A. et al.2022Nature Communications
13 (1), 2442
10.1038/s41467-022-30134-9
Impact of non-pharmaceutical interventions on SARS-CoV-2 outbreaks in English care homes: a modelling studyRosello A. et al.2022BMC Infectious Diseases
22 (1), 324
10.1186/s12879-022-07268-8
Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19Faucher B. et al.2022Nature Communications
13 (1), 1414
10.1038/s41467-022-29015-y
Antibody escape and global spread of SARS-CoV-2 lineage A.27Kaleta T. et al.2022Nature Communications
13 (1), 1152
10.1038/s41467-022-28766-y
Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to FranceBosetti P. et al.2022BMC Medicine
20 (1), 33
10.1186/s12916-022-02235-1
Rapid antigen testing as a reactive response to surges in nosocomial SARS-CoV-2 outbreak riskSmith D.R.M. et al.2022Nature Communications
13 (1), 236
10.1038/s41467-021-27845-w
No durable impact of COVID-19 measures on the hospital burden of respiratory syncytial virus (France, 2018–2022)Fourgeaud J. et al.2022Journal of Infection
85 (4), pp. 436-480
10.1016/j.jinf.2022.06.019
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosaVesin B. et al.2022Molecular Therapy
30 (9), pp. 2984-2997
10.1016/j.ymthe.2022.04.016
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort studyBruel T. et al.2022eClinicalMedicine
51, 101576
10.1016/j.eclinm.2022.101576
Bronchiolitis epidemics in France during the SARS-CoV-2 pandemic: The 2020–2021 and 2021–2022 seasonsVaux S. et al.2022Infectious Diseases Now
52 (6), pp. 374-378
10.1016/j.idnow.2022.06.003
Olfactory outcomes in Zika virus-associated Guillain–Barré syndromeLazarini F. et al.2022European Journal of Neurology
29 (9), pp. 2823-2831
10.1111/ene.15444
Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al' by Pino et alOuldali N. et al.2022Annals of the Rheumatic Diseases
81 (9), e160
10.1136/annrheumdis-2020-218614
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primatesMarlin R. et al.2022Nature communications
13 (1), pp. 5108
10.1038/s41467-022-32565-w
The genetic and evolutionary determinants of COVID-19 susceptibilityKerner G. ; Quintana-Murci L.2022European Journal of Human Genetics
30 (8), pp. 915-921
10.1038/s41431-022-01141-7
Aspergillus detection in airways of ICU COVID-19 patients: To treat or not to treat?Bounhiol A. ; Pasquier G. ; Novara A. ; Bougnoux M.E. ; Dannaoui E.2022Journal of Medical Mycology
32 (3), 101290
10.1016/j.mycmed.2022.101290
Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximabMorel A. et al.2022American Journal of Transplantation
22 (8), pp. 2099-2103
10.1111/ajt.17000
Author Correction: Bat coronaviruses related to SARS-CoV-2 and infectious for human cells (Nature, (2022), 604, 7905, (330-336), 10.1038/s41586-022-04532-4)Temmam S. et al.2022Nature
607 (7920), pp. E19
10.1038/s41586-022-05048-7
Tunneling nanotubes provide a route for SARS-CoV-2 spreadingPepe A. ; Pietropaoli S. ; Vos M. ; Barba-Spaeth G. ; Zurzolo C.2022Science Advances
8 (29), eabo0171
10.1126/sciadv.abo0171
C910 chemical compound inhibits the traffiking of several bacterial AB toxins with cross-protection against influenza virusWu Y. et al.2022iScience
25 (7), 104537
10.1016/j.isci.2022.104537
A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 MiceBrandys P. et al.2022Frontiers in Immunology
13, 912898
10.3389/fimmu.2022.912898
Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2Planchais C. et al.2022Journal of Experimental Medicine
219 (7), e20220638
10.1084/jem.20220638
A close shave: How SARS-CoV-2 induces the loss of ciliaFonseca B.F. ; Chakrabarti L.A.2022Journal of Cell Biology
221 (7), e202206023
10.1083/jcb.202206023
Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat CellsAicher S.M. et al.2022Journal of Virology
96 (14)
10.1128/jvi.00608-22
Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and VaccinationGarcia L. et al.2022Viruses
14 (7), 1491
10.3390/v14071491
Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2– Recovered Dialysis PatientsAttias P. et al.2022Clinical Journal of the American Society of Nephrology
17 (7), pp. 1008-1016
10.2215/CJN.00830122
Modelling the response to vaccine in nonhuman primates to define SARS-CoV-2 mechanistic correlates of protectionAlexandre M. et al.2022eLife
11, e75427
10.7554/elife.75427
Measuring Basic Reproduction Number to Assess Effects of Nonpharmaceutical Interventions on Nosocomial SARS-CoV-2 TransmissionShirreff G. ; Zahar J.R. ; Cauchemez S. ; Temime L. ; Opatowski L.2022Emerging Infectious Diseases
28 (7), pp. 1345-1354
10.3201/eid2807.212339
Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replicationTsuji G. et al.2022Journal of Pharmacological Sciences
149 (3), pp. 81-84
10.1016/j.jphs.2022.04.001
Screening and vaccination against COVID-19 to minimise school closure: a modelling studyColosi E. et al.2022The Lancet Infectious Diseases
22 (7), pp. 977-989
10.1016/S1473-3099(22)00138-4
Aedes mosquitoes in the emerging threat of urban yellow fever transmissionGabiane G. ; Yen P.S. ; Failloux A.B.2022Reviews in Medical Virology
32 (4), e2333
10.1002/rmv.2333
Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: Strengths, challenges, and lessons learnedBagaria J. et al.2022Eurosurveillance
27 (26), 2100864
10.2807/1560-7917.ES.2022.27.26.2100864
Early IFNβ secretion determines variable downstream IL-12p70 responses upon TLR4 activationPosseme C. et al.2022Cell Reports
39 (13), 110989
10.1016/j.celrep.2022.110989
Association between the COVID-19 pandemic and pertussis derived from multiple nationwide data sources, France, 2013 to 2020Matczak S. et al.2022Eurosurveillance
27 (25), 2100933
10.2807/1560-7917.ES.2022.27.25.2100933
COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infectionBoudhabhay I. et al.2022Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
37 (7), pp. 1357-1365
10.1093/ndt/gfac016
Comparing the age and sex trajectories of SARS-CoV-2 morbidity and mortality with other respiratory pathogensMetcalf C.J.E. et al.2022Royal Society Open Science
9 (6), 211498
10.1098/rsos.211498
Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variantSokal A. et al.2022Immunity
55 (6), pp. 1096-1104.e4
10.1016/j.immuni.2022.04.002
Two Separate Clusters of SARS-CoV-2 Delta Variant Infections in A Group of 41 Students Travelling from India: An Illustration of the Need for Rigorous Testing and QuarantineVan Elslande J. et al.2022Viruses
14 (6), 1198
10.3390/v14061198
Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral MucormycosisSerris A. et al.2022Frontiers in Immunology
13, 900522
10.3389/fimmu.2022.900522
Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic OptionsZnaidia M. ; Demeret C. ; van der Werf S. ; Komarova A.V.2022Viruses
14 (6), 1247
10.3390/v14061247
Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with chronic inflammatory rheumatic diseasesGros C. et al.2022Revue du Rhumatisme (Edition Francaise)
89 (4), pp. 405-411
10.1016/j.rhum.2022.04.010
Public health issues and health rendezvous for migrants from conflict zones in Ukraine: A French practice guidelineVignier N. et al.2022Infectious Diseases Now
52 (4), pp. 193-201
10.1016/j.idnow.2022.04.006
An early warning system for emerging SARS-CoV-2 variantsSubissi L. et al.2022Nature Medicine
28 (6), pp. 1110-1115
10.1038/s41591-022-01836-w
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodiesBruel T. et al.2022Nature Medicine
28 (6), pp. 1297-1302
10.1038/s41591-022-01792-5
Is SARS-CoV-2 seroconversion a risk factor for severe and acute psychiatric symptoms in children?Ayrolles A. et al.2022Neuropsychopharmacology Reports
42 (2), pp. 218-220
10.1002/npr2.12236
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021Kissling E. et al.2022Eurosurveillance
27 (21), A1
10.2807/1560-7917.ES.2022.27.21.2101104
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesManry J. et al.2022Proceedings of the National Academy of Sciences of the United States of America
119 (21), e2200413119
10.1073/pnas.2200413119
Trends in bacterial sepsis incidence and mortality in France between 2015 and 2019 based on National Health Data System (Système National des données de Santé (SNDS)): a retrospective observational studyPandolfi F. ; Guillemot D. ; Watier L. ; Brun-Buisson C.2022BMJ Open
12 (5), e058205
10.1136/bmjopen-2021-058205
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibodyTorres J.L. et al.2022Proceedings of the National Academy of Sciences of the United States of America
119 (20), e2120976119
10.1073/pnas.2120976119
Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2Auerswald H. et al.2022Frontiers in Medicine
9, 864972
10.3389/fmed.2022.864972
A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate ModelFovet C.M. et al.2022Frontiers in Immunology
13, 855230
10.3389/fimmu.2022.855230
An ensemble model based on early predictors to forecast COVID-19 health care demand in FrancePaireau J. et al.2022Proceedings of the National Academy of Sciences of the United States of America
119 (18), e2103302119
10.1073/pnas.2103302119
Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against COVID-19 and the urgent need of a large immunization in healthcare workersChouchana L. et al.2022Therapies
77 (3), pp. 371-373
10.1016/j.therap.2021.07.004
SARS-CoV-2 Lineage A.27: New Data from African Countries and Dynamics in the Context of the COVID-19 PandemicChouikha A. et al.2022Viruses
14 (5), 1007
10.3390/v14051007
Selection for infectivity profiles in slow and fast epidemics, and the rise of SARS-CoV-2 variantsBlanquart F. ; Hozé N. ; Cowling B.J. ; Débarre F. ; Cauchemez S.2022eLife
11, e75791
10.7554/eLife.75791
Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: Update of a living systematic review and meta-analysisBuitrago-Garcia D. et al.2022PLoS Medicine
19 (5), e1003987
10.1371/journal.pmed.1003987
What drives willingness to receive a new vaccine that prevents an emerging infectious disease? A discrete choice experiment among university students in UgandaBonner K.E. et al.2022PLoS ONE
17 (5 May), e0268063
10.1371/journal.pone.0268063
Studying severe long COVID to understand post-infectious disorders beyond COVID-19Brodin P. et al.2022Nature Medicine
28 (5), pp. 879-882
10.1038/s41591-022-01766-7
Outpatient Antibiotic Prescriptions in France: Patients and Providers Characteristics and Impact of the COVID-19 PandemicBara W. ; Brun-Buisson C. ; Coignard B. ; Watier L.2022Antibiotics
11 (5), 643
10.3390/antibiotics11050643
Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in FranceDecarreaux D. et al.2022Viruses
14 (5), 957
10.3390/v14050957
A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare projectMolino D. et al.2022Nature Medicine
28 (5), pp. 882-884
10.1038/s41591-022-01785-4
Changes in Invasive Neisseria meningitidis and Haemophilus influenzae Infections in France during the COVID-19 PandemicDeghmane A.E. ; Taha M.K.2022Microorganisms
10 (5), 907
10.3390/microorganisms10050907
Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling studyChen Y. et al.2022The Lancet Infectious Diseases
22 (5), pp. 657-667
10.1016/S1473-3099(22)00025-1
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipientsBenotmane I. et al.2022Kidney International
101 (5), pp. 1073-1076
10.1016/j.kint.2022.02.011
A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitorsChen K.Y. et al.2022Antiviral Research
201, 105272
10.1016/j.antiviral.2022.105272
Intranasal delivery of SARS-CoV-2 spike protein is sufficient to cause olfactory damage, inflammation and olfactory dysfunction in zebrafishKraus A. et al.2022Brain, Behavior, and Immunity
102, pp. 341-359
10.1016/j.bbi.2022.03.006
Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell DisordersRossignol J. et al.2022Journal of Allergy and Clinical Immunology: In Practice
10 (5), pp. 1356-1364.e2
10.1016/j.jaip.2021.12.038
First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022Maisa A. et al.2022Infectious Diseases Now
52 (3), pp. 160-164
10.1016/j.idnow.2022.02.003
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseasesHadjadj J. et al.2022Annals of the rheumatic diseases
81 (5), pp. 720-728
10.1136/annrheumdis-2021-221508
Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseasesGros C. et al.2022Joint Bone Spine
89 (3), 105312
10.1016/j.jbspin.2021.105312
Bat coronaviruses related to SARS-CoV-2 and infectious for human cellsTemmam S. et al.2022Nature
604 (7905), pp. 330-336
10.1038/s41586-022-04532-4
Pertussis surveillance results from a French general practitioner network, France, 2017 to 2020Debin M. et al.2022Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
27 (17)
10.2807/1560-7917.ES.2022.27.17.2100515
Social conformism and confidence in systems as additional psychological antecedents of vaccination: a survey to explain intention for COVID-19 vaccination among healthcare and welfare sector workers, France, December 2020 to February 2021Moirangthem S. et al.2022Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
27 (17)
10.2807/1560-7917.ES.2022.27.17.2100617
COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the General Population of the Capital City TunisCherif I. et al.2022Diagnostics
12 (4), 971
10.3390/diagnostics12040971
Contributions of modelling for the control of COVID-19 nosocomial transmissionOpatowski L. ; Temime L.2022Anaesthesia Critical Care and Pain Medicine
41 (2), 101054
10.1016/j.accpm.2022.101054
Epidemic models: why and how to use themSofonea M.T. ; Cauchemez S. ; Boëlle P.Y.2022Anaesthesia Critical Care and Pain Medicine
41 (2), 101048
10.1016/j.accpm.2022.101048
Towards SARS-CoV-2 serotypes?Simon-Loriere E. ; Schwartz O.2022Nature Reviews Microbiology
20 (4), pp. 187-188
10.1038/s41579-022-00708-x
Sensitive visualization of SARS-CoV-2 RNA with CoronaFISHRensen E. et al.2022Life Science Alliance
5 (4), 202101124
10.26508/lsa.202101124
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosusMoyon Q. et al.2022Annals of the rheumatic diseases
81 (4), pp. 575-583
10.1136/annrheumdis-2021-221097
Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022Bastard J. et al.2022Eurosurveillance
27 (13)
10.2807/1560-7917.ES.2022.27.13.2200247
The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia FormationRajah M.M. ; Bernier A. ; Buchrieser J. ; Schwartz O.2022Journal of Molecular Biology
434 (6), 167280
10.1016/j.jmb.2021.167280
Discovery of Genes that Modulate Flavivirus Replication in an Interferon-Dependent Manner: Effectors of the anti-flavivirus responseLesage S. et al.2022Journal of Molecular Biology
434 (6), 167277
10.1016/j.jmb.2021.167277
Human genetic and immunological determinants of critical COVID-19 pneumoniaZhang Q. et al.2022Nature
603 (7902), pp. 587-598
10.1038/s41586-022-04447-0
Association between growth of the SARS-CoV-2 epidemic and increased coughing rate in cold temperatures: Surveillance in Hokkaido, JapanInaida S. ; Paul R.2022BMJ Open
12 (3), e051534
10.1136/bmjopen-2021-051534
Exploring Zebrafish Larvae as a COVID-19 Model: Probable Abortive SARS-CoV-2 Replication in the Swim BladderLaghi V. et al.2022Frontiers in Cellular and Infection Microbiology
12, 790851
10.3389/fcimb.2022.790851
COVID-19 vaccination, time for a second breath?Gerke C.E. ; Pulverer B. ; Sansonetti P.J.2022EMBO Molecular Medicine
14 (3), e15810
10.15252/emmm.202215810
SARS-CoV-2 Omicron emergence urges for reinforced One-Health surveillanceMontagutelli X. ; van der Werf S. ; Rey F.A. ; Simon-Loriere E.2022EMBO Molecular Medicine
14 (3), e15558
10.15252/emmm.202115558
COVID-19 and the Burden of Confinement on Women’s Health: A Comparison between France and the United StatesMerchant J. ; Vidal C.2022International Journal of Feminist Approaches to Bioethics
15 (1), pp. 119-122
10.3138/ijfab-15.1.14
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2Saunders N. et al.2022eBioMedicine
77, 103934
10.1016/j.ebiom.2022.103934
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' replyGangneux J.P. et al.2022The Lancet Respiratory Medicine
10 (3), pp. e27
10.1016/S2213-2600(22)00048-0
sgDI-tector: Defective interfering viral genome bioinformatics for detection of coronavirus subgenomic RNAsDi Gioacchino A. et al.2022RNA
28 (3), pp. 277-289
10.1261/rna.078969.121
Combination of Mycological Criteria: a Better Surrogate to Identify COVID-19-Associated Pulmonary Aspergillosis Patients and Evaluate Prognosis?Dellière S. et al.2022Journal of Clinical Microbiology
60 (3), e02169-21
10.1128/jcm.02169-21
Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent mannerGarnier Y. et al.2022British Journal of Haematology
196 (5), pp. 1159-1169
10.1111/bjh.18019
Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trialDelaugerre C. et al.2022The Lancet Infectious Diseases
22 (3), pp. 341-348
10.1016/S1473-3099(21)00673-3
Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative reviewAlderson M.R. et al.2022Journal of Infection
84 (3), pp. 289-296
10.1016/j.jinf.2021.11.016
COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature reviewBenhadid-Brahmi Y. et al.2022Journal of Medical Mycology
32 (1), 101231
10.1016/j.mycmed.2021.101231
SARS-CoV-2 Induces Cytokine Responses in Human BasophilsBonam S.R. et al.2022Frontiers in Immunology
13, 838448
10.3389/fimmu.2022.838448
Considerable escape of SARS-CoV-2 Omicron to antibody neutralizationPlanas D. et al.2022Nature
602 (7898), pp. 671-675
10.1038/s41586-021-04389-z
Interactions of Severe Acute Respiratory Syndrome Coronavirus 2 Protein E With Cell Junctions and Polarity PSD-95/Dlg/ZO-1-Containing ProteinsZhu Y. et al.2022Frontiers in Microbiology
13, 829094
10.3389/fmicb.2022.829094
Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 VaccineGallais F. et al.2022Frontiers in Immunology
13, 790212
10.3389/fimmu.2022.790212
Conditionality of COVID-19 vaccine acceptance in European countriesHeyerdahl L.W. et al.2022Vaccine
40 (9), pp. 1191-1197
10.1016/j.vaccine.2022.01.054
Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling studyDiarra M. et al.2022BMJ Global Health
7 (2), e007236
10.1136/bmjgh-2021-007236
The Synaptic Gene Study: Design and Methodology to Identify Neurocognitive Markers in Phelan-McDermid Syndrome and NRXN1 DeletionsCooke J. et al.2022Frontiers in Neuroscience
16, 806990
10.3389/fnins.2022.806990
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infectionSulbaran G. et al.2022Cell Reports Medicine
3 (2), 100528
10.1016/j.xcrm.2022.100528
Editorial: Balanced and Unbalanced Immune Response to Dengue Virus in Disease Protection and PathogenesisCantaert T. ; Jouvenet N. ; Diehl S.A.2022Frontiers in Immunology
13, 835731
10.3389/fimmu.2022.835731
Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-NeutralisationMiyara M. et al.2022Frontiers in Immunology
13, 790334
10.3389/fimmu.2022.790334
Early chains of transmission of COVID-19 in France, January to March 2020Paireau J. et al.2022Eurosurveillance
27 (6), 2001953
10.2807/1560-7917.ES.2022.27.6.2001953
Epidemiological and clinical insights from SARS-CoV-2 RT-PCR crossing threshold values, France, January to November 2020Alizon S. et al.2022Eurosurveillance
27 (6), 2100406
10.2807/1560-7917.ES.2022.27.6.2100406
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myelomaHenriquez S. et al.2022Blood
139 (6), pp. 942-946
10.1182/blood.2021013714
Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal CohortVo H.T.M. et al.2022Frontiers in Immunology
13, 817905
10.3389/fimmu.2022.817905
A virus-derived microRNA targets immune response genes during SARS-CoV-2 infectionSingh M. et al.2022EMBO Reports
23 (2), e54341
10.15252/embr.202154341
Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly ComplicationDanion F. et al.2022Open Forum Infectious Diseases
9 (2), ofab566
10.1093/ofid/ofab566
FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17DScheck M.K. et al.2022PLoS ONE
17 (2 February), e0262149
10.1371/journal.pone.0262149
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID studyGangneux J.P. et al.2022The Lancet Respiratory Medicine
10 (2), pp. 180-190
10.1016/S2213-2600(21)00442-2
High negative predictive value of RT-PCR in patients with high likelihood of SARS-CoV-2 infectionGalmiche S. et al.2022Infectious Diseases Now
52 (1), pp. 52-53
10.1016/j.idnow.2021.11.005
Severe COVID-19 is associated with hyperactivation of the alternative complement pathwayBoussier J. et al.2022Journal of Allergy and Clinical Immunology
149 (2), pp. 550-556.e2
10.1016/j.jaci.2021.11.004
Is the Alpha Variant of SARS-CoV-2 Associated with a Higher Viral Load Than the Historical Strain in Saliva Samples in Patients with Mild to Moderate Symptoms?Bonnet C. et al.2022Life
12 (2), 163
10.3390/life12020163
Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in FranceGrant R. et al.2022The Lancet Regional Health - Europe
13, 100278
10.1016/j.lanepe.2021.100278
Author Correction: A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection (Nature Immunology, (2022), 23, 2, (159-164), 10.1038/s41590-021-01030-z)Andreakos E. et al.2022Nature Immunology
23 (2), pp. 341
10.1038/s41590-021-01096-9
A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational studyFillâtre P. et al.2022Clinical Microbiology and Infection
28 (2), pp. 298.e9-298.e15
10.1016/j.cmi.2021.09.035
A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infectionAndreakos E. et al.2022Nature Immunology
23 (2), pp. 159-164
10.1038/s41590-021-01030-z
The Impact of Cocirculating Pathogens on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Coronavirus Disease 2019 Surveillance: How Concurrent Epidemics May Introduce Bias and Decrease the Observed SARS-CoV-2 Percentage PositivityKovacevic A. ; Eggo R.M. ; Baguelin M. ; Domenech De Cellès M. ; Opatowski L.2022Journal of Infectious Diseases
225 (2), pp. 199-207
10.1093/infdis/jiab459
Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22Bosetti P. et al.2022Eurosurveillance
27 (1), 2101125
10.2807/1560-7917.ES.2022.27.1.2101125
SARS-CoV-2 exposures of healthcare workers from primary care, long-term care facilities and hospitals: a nationwide matched case-control studyBelan M. et al.2022Clinical Microbiology and Infection10.1016/j.cmi.2022.05.038
Saliva for molecular detection of SARS-CoV-2 in pre-school and school-age childrenDelaunay-Moisan A. et al.2022Environmental Microbiology10.1111/1462-2920.16151
Association of Nonpharmaceutical Interventions during the COVID-19 Pandemic with Invasive Pneumococcal Disease, Pneumococcal Carriage, and Respiratory Viral Infections among Children in FranceRybak A. et al.2022JAMA Network Open
, pp. E2218959
10.1001/jamanetworkopen.2022.18959
Postscript: A pandemic read on African health and environmental historiesGiles-Vernick T.2022Health and Place
, 102846
10.1016/j.healthplace.2022.102846
Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experimentSicsic J. ; Blondel S. ; Chyderiotis S. ; Langot F. ; Mueller J.E.2022European Journal of Health Economics10.1007/s10198-022-01454-w
BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2Samelson A.J. et al.2022Nature Cell Biology
24 (1), pp. 24-34
10.1038/s41556-021-00821-8
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I studyLaunay O. et al.2022eBioMedicine
75, 103810
10.1016/j.ebiom.2021.103810
Publisher Correction: Monitoring key epidemiological parameters of SARS-CoV-2 transmission (Nature Medicine, (2021), 27, 11, (1854-1855), 10.1038/s41591-021-01545-w)Kraemer M.U.G. et al.2022Nature Medicine
28 (1), pp. 213
10.1038/s41591-021-01670-6
Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoproteinGransagne M. et al.2022Journal of Biological Chemistry
298 (1), 101290
10.1016/j.jbc.2021.101290
Nicotinic receptors as SARS-CoV-2 spike co-receptors?Dormoy V. et al.2022Medical Hypotheses
158, 110741
10.1016/j.mehy.2021.110741
Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccinesOliu-Barton M. et al.2022The Lancet Global Health
10 (1), pp. e142-e147
10.1016/S2214-109X(21)00494-0
Rethinking the Infodemic: Social Media and Offline Action in the COVID-19 PandemicHeyerdahl L.W. ; Lana B. ; Giles-Vernick T.2022Economics, Law, and Institutions in Asia Pacific
, pp. 73-82
10.1007/978-981-16-5727-6_4
The COVID-19 Outbreak and Public Health Issues: An Interdisciplinary ApproachSakuntabhai A. ; Thomann B.2022Economics, Law, and Institutions in Asia Pacific
, pp. 341-353
10.1007/978-981-16-5727-6_15
Integrating Social Sciences to Mitigate Against CovidPaul R. ; Telle O. ; Benkimoun S.2022Economics, Law, and Institutions in Asia Pacific
, pp. 47-71
10.1007/978-981-16-5727-6_3
Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 InfectionRodero M.P. et al.2022Journal of Clinical Immunology
42 (1), pp. 25-27
10.1007/s10875-021-01119-y
Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteasesTekpinar M. ; Yildirim A.2022Journal of Biomolecular Structure and Dynamics
40 (14), pp. 6243-6254
10.1080/07391102.2021.1880481
Mathematical modelling of SARS-CoV-2 infection of human and animal host cells reveals differences in the infection rates and delays in viral particle production by infected cellsBernhauerová V. ; Lisowski B. ; Rezelj V.V. ; Vignuzzi M.2021Journal of Theoretical Biology
531, 110895
10.1016/j.jtbi.2021.110895
Mapping the human genetic architecture of COVID-19Niemi M.E.K. et al.2021Nature
600 (7889), pp. 472-477
10.1038/s41586-021-03767-x
SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formationRajah M.M. et al.2021EMBO Journal
40 (24), e108944
10.15252/embj.2021108944
mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variantsSokal A. et al.2021Immunity
54 (12), pp. 2893-2907.e5
10.1016/j.immuni.2021.09.011
Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic miceKu M.W. et al.2021EMBO Molecular Medicine
13 (12), e14459
10.15252/emmm.202114459
Estimating the impact of influenza on the epidemiological dynamics of SARS-CoV-2De Cellès M.D. ; Casalegno J.S. ; Lina B. ; Opatowski L.2021PeerJ
9, e12566
10.7717/peerj.12566
Lockdown impact on age-specific contact patterns and behaviours, France, April 2020Bosetti P. et al.2021Eurosurveillance
26 (48), 2001636
10.2807/1560-7917.ES.2021.26.48.2001636
Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patientsCrescenzo-Chaigne B. et al.2021Journal of Clinical Virology Plus
1 (4), 100041
10.1016/j.jcvp.2021.100041
Influenza viruses and coronaviruses: Knowns, unknowns, and common research challengesTerrier O. et al.2021PLoS Pathogens
17 (12), e1010106
10.1371/journal.ppat.1010106
An anti-Covid-19 lentiviral vaccine candidate that can be administered by the nasal routeMajlessi L. ; Charneau P.2021Medecine/Sciences
37 (12), pp. 1172-1175
10.1051/medsci/2021173
Myocardial involvement in children with post-COVID multisystem inflammatory syndrome: a cardiovascular magnetic resonance based multicenter international study—the CARDOVID registryAeschlimann F.A. et al.2021Journal of Cardiovascular Magnetic Resonance
23 (1), 140
10.1186/s12968-021-00841-1
Aspergillus test profiles and mortality in critically ill covid-19 patientsErgün M. et al.2021Journal of Clinical Microbiology
59 (12), e01229-21
10.1128/JCM.01229-21
Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)Weiss A. et al.2021PLoS ONE
16 (12 December), e0260958
10.1371/journal.pone.0260958
SARS-CoV-2 transmission across age groups in France and implications for controlTran Kiem C. et al.2021Nature Communications
12 (1), 6895
10.1038/s41467-021-27163-1
Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an emergency departmentNguyenVan J.C. et al.2021Journal of Clinical Virology
145, 105021
10.1016/j.jcv.2021.105021
Using secondary cases to characterize the severity of an emerging or re-emerging infectionTsang T.K. ; Wang C. ; Yang B. ; Cauchemez S. ; Cowling B.J.2021Nature Communications
12 (1), 6372
10.1038/s41467-021-26709-7
A novel SARS-CoV-2 related coronavirus in bats from CambodiaDelaune D. et al.2021Nature Communications
12 (1), 6563
10.1038/s41467-021-26809-4
Clash of the titans: interferons and SARS-CoV-2Jouvenet N. ; Goujon C. ; Banerjee A.2021Trends in Immunology
42 (12), pp. 1069-1072
10.1016/j.it.2021.10.009
A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamstersFrantz P.N. et al.2021Nature Communications
12 (1), 6277
10.1038/s41467-021-26506-2
Evaluation of a saliva molecular point of care for the detection of SARS-CoV-2 in ambulatory careLeGoff J. et al.2021Scientific Reports
11 (1), 21126
10.1038/s41598-021-00560-8
A cross-sectional analysis of meteorological factors and SARS-CoV-2 transmission in 409 cities across 26 countriesSera F. et al.2021Nature Communications
12 (1), 5968
10.1038/s41467-021-25914-8
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical modelsMaisonnasse P. et al.2021Nature Communications
12 (1), 6097
10.1038/s41467-021-26354-0
Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak*Frumholtz L. et al.2021British Journal of Dermatology
185 (6), pp. 1176-1185
10.1111/bjd.20707
Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletionsDudas G. et al.2021Nature Communications
12 (1), 5769
10.1038/s41467-021-26055-8
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potentialMeyer B. et al.2021Nature Communications
12 (1), 5553
10.1038/s41467-021-25796-w
Analysis of T-cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in patients with chilblain-like lesions during the COVID-19 pandemicCassius C. et al.2021British Journal of Dermatology
185 (6), pp. 1242-1244
10.1111/bjd.20647
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaquesMarlin R. et al.2021Nature Communications
12 (1), 5215
10.1038/s41467-021-25382-0
Impact of COVID-19 social distancing on viral infection in France: A delayed outbreak of RSVDelestrain C. et al.2021Pediatric Pulmonology
56 (12), pp. 3669-3673
10.1002/ppul.25644
SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearanceRobinot R. et al.2021Nature Communications
12 (1), 4354
10.1038/s41467-021-24521-x
Platelet activation in critically ill COVID-19 patientsYatim N. et al.2021Annals of Intensive Care
11 (1), 113
10.1186/s13613-021-00899-1
Whole genome sequencing and phylogenetic analysis of six SARS-CoV-2 strains isolated during COVID-19 pandemic in Tunisia, North AfricaFares W. et al.2021BMC Genomics
22 (1), 540
10.1186/s12864-021-07870-1
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosisGoubet A.G. et al.2021Cell Death and Differentiation
28 (12), pp. 3297-3315
10.1038/s41418-021-00817-9
Cold and dry winter conditions are associated with greater SARS-CoV-2 transmission at regional level in western countries during the first epidemic waveLandier J. et al.2021Scientific Reports
11 (1), 12756
10.1038/s41598-021-91798-9
Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patientsCourties A. et al.2021Scientific Reports
11 (1), 11886
10.1038/s41598-021-91417-7
Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxychloroquine in French healthcare workers during the first wave of COVID-19 pandemicGagneux-Brunon A. et al.2021Trials
22 (1), 373
10.1186/s13063-021-05329-y
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillanceLe Vu S. et al.2021Nature Communications
12 (1), 3025
10.1038/s41467-021-23233-6
Lessons learned from the investigation of a COVID-19 cluster in Creil, France: effectiveness of targeting symptomatic cases and conducting contact tracing around themde Laval F. et al.2021BMC Infectious Diseases
21 (1), 457
10.1186/s12879-021-06166-9
Author Correction: Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers (Nature Communications, (2021), 12, 1, (844), 10.1038/s41467-021-21111-9)Marot S. et al.2021Nature Communications
12 (1), 2824
10.1038/s41467-021-23128-6
Deciphering the state of immune silence in fatal COVID-19 patientsBost P. et al.2021Nature Communications
12 (1), 1428
10.1038/s41467-021-21702-6
Evaluating the impact of curfews and other measures on SARS-CoV-2 transmission in French GuianaAndronico A. et al.2021Nature Communications
12 (1), 1634
10.1038/s41467-021-21944-4
Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workersMarot S. et al.2021Nature Communications
12 (1), 844
10.1038/s41467-021-21111-9
Guidelines of the French Society of Otorhinolaryngology and Head and Neck Surgery (SFORL) for teleconsultation in patients with vertigo during the COVID-19 pandemicBertholon P. et al.2021Annales Francaises d'Oto-Rhino-Laryngologie et de Pathologie Cervico-Faciale
138 (6), pp. 462-468
10.1016/j.aforl.2020.10.002
Guidelines of the French Society of Otorhinolaryngology (SFORL) for teleconsultation in patients with vertigo during the COVID-19 pandemicBertholon P. et al.2021European Annals of Otorhinolaryngology, Head and Neck Diseases
138 (6), pp. 459-465
10.1016/j.anorl.2020.11.011
Atypical Prolonged Viral Shedding With Intra-Host SARS-CoV-2 Evolution in a Mildly Affected Symptomatic PatientCunha M.d.P. et al.2021Frontiers in Medicine
8, 760170
10.3389/fmed.2021.760170
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes VariantsVanhove B. et al.2021Frontiers in Immunology
12, 761250
10.3389/fimmu.2021.761250
Two-photon microscopy analysis reveals different pulmonary damage after infection by influenza or SARS-CoV-2Rivière F. et al.2021Respiratory Medicine and Research
80, 100862
10.1016/j.resmer.2021.100862
MALVIRUS: an integrated application for viral variant analysisCiccolella S. et al.2021BMC Bioinformatics
22, 625
10.1186/s12859-022-04668-0
Two-photon microscopy analysis reveals different pulmonary damage after infection by influenza or SARS-CoV-2Frédéric R. et al.2021Respiratory medicine and research
80, pp. 100862
10.1016/j.resmer.2021.100862
Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time since InfectionPelleau S. et al.2021Journal of Infectious Diseases
224 (9), pp. 1489-1499
10.1093/infdis/jiab375
Seroprevalence of anti-sars-cov-2 igg at the first epidemic peak in french guiana, july 2020Flamand C. et al.2021PLoS Neglected Tropical Diseases
15 (11), e0009945
10.1371/journal.pntd.0009945
Highly Sensitive Quantification of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its Potential Clinical ValueVeyer D. et al.2021Clinical Infectious Diseases
73 (9), pp. E2890-E2897
10.1093/cid/ciaa1196
Pdz-containing proteins targeted by the ace2 receptorCaillet-Saguy C. ; Wolff N.2021Viruses
13 (11), 2281
10.3390/v13112281
Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumoniaGhanem M. et al.2021American Journal of Physiology - Lung Cellular and Molecular Physiology
321 (5), pp. L847-L858
10.1152/ajplung.00545.2020
“We Tried to Borrow Money, but No One Helped.” Assessing the Three-Delay Model Factors Affecting the Healthcare Service Delivery among Dengue Patients during COVID-19 Surge in a Public Tertiary Hospital: A Convergent Parallel Mixed Methods StudyLigsay A.D. et al.2021International Journal of Environmental Research and Public Health
18 (22), 11851
10.3390/ijerph182211851
Monitoring key epidemiological parameters of SARS-CoV-2 transmissionKraemer M.U.G. et al.2021Nature Medicine
27 (11), pp. 1854-1855
10.1038/s41591-021-01545-w
Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in FranceLefèvre B. et al.2021The Lancet Healthy Longevity
2 (11), pp. e685-e687
10.1016/S2666-7568(21)00230-0
Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patientsSacconi A. et al.2021Cell Death and Disease
12 (11), 1019
10.1038/s41419-021-04299-y
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective studyMonel B. et al.2021EBioMedicine
73, 103637
10.1016/j.ebiom.2021.103637
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infectionSmith N. et al.2021Nature Immunology
22 (11), pp. 1428-1439
10.1038/s41590-021-01028-7
Accuracy of saliva and nasopharyngeal sampling for detection of SARS-CoV-2 in community screening: a multicentric cohort studyKernéis S. et al.2021European Journal of Clinical Microbiology and Infectious Diseases
40 (11), pp. 2379-2388
10.1007/s10096-021-04327-x
Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in FranceFourgeaud J. et al.2021European Journal of Clinical Microbiology and Infectious Diseases
40 (11), pp. 2389-2395
10.1007/s10096-021-04323-1
Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital MortalityGendron N. et al.2021Arthritis and Rheumatology
73 (11), pp. 1976-1985
10.1002/art.41777
Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trialsDautzenberg B. ; Levi A. ; Adler M. ; Gaillard R.2021Respiratory Medicine and Research
80, 100844
10.1016/j.resmer.2021.100844
Educational Setting and SARS-CoV-2 Transmission Among Children With Multisystem Inflammatory Syndrome: A French National Surveillance SystemGuenver C. et al.2021Frontiers in Pediatrics
9, 745364
10.3389/fped.2021.745364
A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in AfricaWilkinson E. et al.2021Science
374 (6566), pp. 423-431
10.1126/science.abj4336
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesWalls A.C. et al.2021Cell
184 (21), pp. 5432-5447.e16
10.1016/j.cell.2021.09.015
Quantifying healthcare and welfare sector workers' preferences around COVID-19 vaccination: A cross-sectional, single-profile discrete-choice experiment in FranceDÍaz Luévano C. et al.2021BMJ Open
11 (10), e055148
10.1136/bmjopen-2021-055148
Covid-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: A retrospective multicenter observational cohort during the first french pandemic waveBretagne S. et al.2021Microbiology Spectrum
9 (2), e01138-21
10.1128/Spectrum.01138-21
COVID-19-related travel restrictions temporarily reduced the demand for rabies post-exposure prophylaxis in FranceParize P. et al.2021Journal of Travel Medicine
28 (7), taab127
10.1093/jtm/taab127
COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanismsOstaszewski M. et al.2021Molecular Systems Biology
17 (10), e10387
10.15252/msb.202110387
New insights into human immunity from ancient genomicsKerner G. ; Patin E. ; Quintana-Murci L.2021Current Opinion in Immunology
72, pp. 116-125
10.1016/j.coi.2021.04.006
Telemedicine in Audiology. Best practice recommendations from the French Society of Audiology (SFA) and the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL)Thai-Van H. et al.2021European Annals of Otorhinolaryngology, Head and Neck Diseases
138 (5), pp. 363-375
10.1016/j.anorl.2020.10.007
Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune responseRoßmann L. et al.2021Proceedings of the National Academy of Sciences of the United States of America
118 (39), e2103651118
10.1073/PNAS.2103651118
Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019Betton M. et al.2021Clinical Infectious Diseases
73 (6), pp. E1337-E1344
10.1093/cid/ciab308
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2Grzelak L. et al.2021Journal of Infectious Diseases
224 (6), pp. 983-988
10.1093/infdis/jiab127
A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditisde Cevins C. et al.2021Med
2 (9), pp. 1072-1092.e7
10.1016/j.medj.2021.08.002
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primatesZabaleta N. et al.2021Cell Host and Microbe
29 (9), pp. 1437-1453.e8
10.1016/j.chom.2021.08.002
Broad sarbecovirus neutralization by a human monoclonal antibodyTortorici M.A. et al.2021Nature
597 (7874), pp. 103-108
10.1038/s41586-021-03817-4
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in FranceCharmet T. et al.2021The Lancet Regional Health - Europe
8, 100171
10.1016/j.lanepe.2021.100171
A bioluminescent 3clpro activity assay to monitor sars-cov-2 replication and identify inhibitorsMathieu C. et al.2021Viruses
13 (9), 1814
10.3390/v13091814
Twelfth Annual ENBDC Workshop: Methods in Mammary Gland Biology and Breast CancerCharifou E. ; Traustadottir G.A. ; Bentires-Alj M. ; Howard B. ; Van Keymeulen A.2021Journal of Mammary Gland Biology and Neoplasia
26 (3), pp. 221-226
10.1007/s10911-021-09498-z
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfectionGallais F. et al.2021EBioMedicine
71, 103561
10.1016/j.ebiom.2021.103561
Managing COVID-19 importation risks in a heterogeneous worldCauchemez S. ; Kiem C.T.2021The Lancet Public Health
6 (9), pp. e626-e627
10.1016/S2468-2667(21)00188-2
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolutionZahradník J. et al.2021Nature Microbiology
6 (9), pp. 1188-1198
10.1038/s41564-021-00954-4
ddPCR increases detection of SARS-CoV-2 RNA in patients with low viral loadsMarchio A. et al.2021Archives of Virology
166 (9), pp. 2529-2540
10.1007/s00705-021-05149-0
Characteristics Associated with Olfactory and Taste Disorders in COVID-19Galmiche S. et al.2021Neuroepidemiology
55 (5), pp. 381-386
10.1159/000517066
A review of significance of Aspergillus detection in airways of ICU COVID-19 patientsPasquier G. et al.2021Mycoses
64 (9), pp. 980-988
10.1111/myc.13341
ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2Van Kerkhove M.D. et al.2021Influenza and other Respiratory Viruses
15 (5), pp. 561-568
10.1111/irv.12870
Long COVID and the brain network of Proust's madeleine: targeting the olfactory pathwayGuedj E. et al.2021Clinical Microbiology and Infection
27 (9), pp. 1196-1198
10.1016/j.cmi.2021.05.015
Host PDZ-containing proteins targeted by SARS-CoV-2Caillet-Saguy C. et al.2021FEBS Journal
288 (17), pp. 5148-5162
10.1111/febs.15881
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1Parellada M. et al.2021Frontiers in Psychiatry
12, 701729
10.3389/fpsyt.2021.701729
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2Drayman N. et al.2021Science
373 (6557), pp. 931-936
10.1126/science.abg5827
Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergenceKraemer M.U.G. et al.2021Science
373 (6557), pp. 889-895
10.1126/science.abj0113
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19Asano T. et al.2021Science Immunology
6 (62), eabl4348
10.1126/sciimmunol.abl4348
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsBastard P. et al.2021Science Immunology
6 (62), eabl4340
10.1126/sciimmunol.abl4340
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationPlanas D. et al.2021Nature
596 (7871), pp. 276-280
10.1038/s41586-021-03777-9
Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectinde Melo G.D. et al.2021EMBO Molecular Medicine
13 (8), e14122
10.15252/emmm.202114122
Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) from a BNT162b2-Vaccinated IndividualKerneís S. et al.2021Open Forum Infectious Diseases
8 (8), ofab369
10.1093/ofid/ofab369
Mitigating COVID-19 outbreaks in workplaces and schools by hybrid telecommutingMauras S. et al.2021PLoS Computational Biology
17 (8), e1009264
10.1371/journal.pcbi.1009264
Covid-19 research: Lessons from non-human primate modelsAlbrecht L. et al.2021Vaccines
9 (8), 886
10.3390/vaccines9080886
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infectionYatim N. et al.2021Science Advances
7 (34), eabg4081
10.1126/sciadv.abg4081
Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern FranceWoudenberg T. et al.2021EBioMedicine
70, 103495
10.1016/j.ebiom.2021.103495
Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control studyGalmiche S. et al.2021The Lancet Regional Health - Europe
7, 100148
10.1016/j.lanepe.2021.100148
Low seroprevalence of COVID-19 in Lao PDR, late 2020Virachith S. et al.2021The Lancet Regional Health - Western Pacific
13, 100197
10.1016/j.lanwpc.2021.100197
A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measuresTran Kiem C. et al.2021eClinicalMedicine
38, 101001
10.1016/j.eclinm.2021.101001
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosisVerweij P.E. et al.2021Intensive Care Medicine
47 (8), pp. 819-834
10.1007/s00134-021-06449-4
The Nexus between Telomere Length and Lymphocyte Count in Seniors Hospitalized with COVID-19Benetos A. et al.2021Journals of Gerontology - Series A Biological Sciences and Medical Sciences
76 (8), pp. E97-E101
10.1093/gerona/glab026
What chikungunya teaches us about COVID-19Simon F. ; Watson H. ; Meynard J.B. ; de Santi V.P. ; Tournier J.N.2021The Lancet Infectious Diseases
21 (8), pp. 1070-1071
10.1016/S1473-3099(21)00272-3
Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?Cohen R. et al.2021Infectious Diseases Now
51 (5), pp. 418-423
10.1016/j.idnow.2021.05.004
Differential serological and neutralizing antibody dynamics after an infection by a single SARS-CoV-2 strainBillon-Denis E. et al.2021Infection
49 (4), pp. 781-783
10.1007/s15010-020-01556-8
Education and mental health: good reasons to vaccinate childrenCauchemez S. et al.2021The Lancet
398 (10298), pp. 387
10.1016/S0140-6736(21)01453-7
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2Tummino T.A. et al.2021Science
373 (6554), 6554
10.1126/science.abi4708
SARS-CoV-2 Nsp3 unique domain SUD interacts with guanine quadruplexes and G4-ligands inhibit this interactionLavigne M. et al.2021Nucleic Acids Research
49 (13), pp. 7695-7712
10.1093/nar/gkab571
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021Kissling E. et al.2021Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
26 (29)
10.2807/1560-7917.ES.2021.26.29.2100670
How did institut pasteur’s ngs core facility, biomics, manage the coronavirus disease 2019 crisis?Najjar I. et al.2021Journal of Biomolecular Techniques
32 (2), pp. 50-56
10.7171/jbt.21-3202-004
A mechanistic and data-driven reconstruction of the time-varying reproduction number: Application to the COVID-19 epidemicCazelles B. et al.2021PLoS Computational Biology
17 (7), e1009211
10.1371/journal.pcbi.1009211
Lives saved with vaccination for 10 pathogens across 112 countries in a pre-covid-19 worldToor J. et al.2021eLife
10, e67635
10.7554/eLife.67635
Nationwide seroprevalence of SARS-CoV-2 IgG antibodies among four groups of primary health-care workers and their household contacts 6 months after the initiation of the COVID-19 vaccination campaign in france: seroPRIM study protocolPouquet M. et al.2021Pathogens
10 (7), 911
10.3390/pathogens10070911
Host-pathogen adhesion as the basis of innovative diagnostics for emerging pathogensvan Belkum A. et al.2021Diagnostics
11 (7), 1259
10.3390/diagnostics11071259
Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: A modelling study, France, May to September 2021Kiem C.T. et al.2021Eurosurveillance
5 (13)
10.2807/1560-7917.ES.2021.26.26.2100533
Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021Tran Kiem C. et al.2021Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
26 (26)
10.2807/1560-7917.ES.2021.26.26.2100533
A review and agenda for integrated disease models including social and behavioural factorsBedson J. et al.2021Nature Human Behaviour
5 (7), pp. 834-846
10.1038/s41562-021-01136-2
SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourseKonings F. et al.2021Nature Microbiology
6 (7), pp. 821-823
10.1038/s41564-021-00932-w
Effectiveness of anaesthesia ventilator use for mechanical ventilation in critically ill patients during the COVID-19 pandemicGouel-Cheron A. et al.2021British Journal of Anaesthesia
127 (1), pp. e35-e37
10.1016/j.bja.2021.04.001
Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020Kissling E. et al.2021Influenza and other Respiratory Viruses
15 (4), pp. 429-438
10.1111/irv.12839
Interoperable medical data: The missing link for understanding COVID-19Bauer D.C. et al.2021Transboundary and Emerging Diseases
68 (4), pp. 1753-1760
10.1111/tbed.13892
COVID-Align: Accurate online alignment of hCoV-19 genomes using a profile HMMLemoine F. ; Blassel L. ; Voznica J. ; Gascuel O.2021Bioinformatics
37 (12), pp. 1761-1762
10.1093/bioinformatics/btaa871
Targeting Polyamines Inhibits Coronavirus Infection by Reducing Cellular Attachment and EntryFirpo M.R. et al.2021ACS Infectious Diseases
7 (6), pp. 1423-1432
10.1021/acsinfecdis.0c00491
COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamstersde Melo G.D. et al.2021Science Translational Medicine
13 (596), eabf8396
10.1126/scitranslmed.abf8396
Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysisLefrancq N. et al.2021The Lancet Regional Health - Europe
5, 100087
10.1016/j.lanepe.2021.100087
Lockdown as a last resort option in case of COVID-19 epidemic rebound: A modelling studyKiem C.T. et al.2021Eurosurveillance
26 (22)
10.2807/1560-7917.ES.2021.26.22.2001536
Ivermectin as a potential treatment for covid-19?Chosidow O. et al.2021PLoS Neglected Tropical Diseases
15 (6), e0009446
10.1371/journal.pntd.0009446
The heterogeneous landscape and early evolution of pathogen-associated CpG dinucleotides in SARS-CoV-2Di Gioacchino A. et al.2021Molecular Biology and Evolution
38 (6), pp. 2428-2445
10.1093/molbev/msab036
COVID-19 containment measures and incidence of invasive bacterial diseaseSmith D.R.M. ; Opatowski L.2021The Lancet Digital Health
3 (6), pp. e331-e332
10.1016/S2589-7500(21)00085-6
Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance dataBrueggemann A.B. et al.2021The Lancet Digital Health
3 (6), pp. e360-e370
10.1016/S2589-7500(21)00077-7
Diversity in immunogenomics: the value and the challengePeng K. et al.2021Nature Methods
18 (6), pp. 588-591
10.1038/s41592-021-01169-5
Structural basis for broad coronavirus neutralizationSauer M.M. et al.2021Nature Structural and Molecular Biology
28 (6), pp. 478-486
10.1038/s41594-021-00596-4
Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling studyHozé N. et al.2021The Lancet Public Health
6 (6), pp. e408-e415
10.1016/S2468-2667(21)00064-5
Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult populationLapidus N. et al.2021Infectious Diseases Now
51 (4), pp. 380-382
10.1016/j.idnow.2020.12.007
High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2Vanhove B. et al.2021European Journal of Immunology
51 (6), pp. 1412-1422
10.1002/eji.202049072
Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortalityBernigaud C. et al.2021British Journal of Dermatology
184 (6), pp. 1207-1209
10.1111/bjd.19821
Heat inactivation of the severe acute respiratory syndrome coronavirus 2Batéjat C. ; Grassin Q. ; Manuguerra J.C. ; Leclercq I.2021Journal of Biosafety and Biosecurity
3 (1), pp. 1-3
10.1016/j.jobb.2020.12.001
Fungal infections should be part of the core outcome set for COVID-19Verweij P.E. ; Alanio A.2021The Lancet Infectious Diseases
21 (6), pp. e145
10.1016/S1473-3099(20)30591-0
High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ householdsFritz M. et al.2021One Health
11, 100192
10.1016/j.onehlt.2020.100192
Ousted health care workers because of COVID-19 infection: Back to work is not an easy moveGOUEL-CHERON A. ; DEN BERGH M.V. ; CRESTANI B. ; MONTRAVERS P.2021Anaesthesia Critical Care and Pain Medicine
40 (3), 100752
10.1016/j.accpm.2020.09.008
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodiesDufloo J. et al.2021Cell Reports Medicine
2 (5), 100275
10.1016/j.xcrm.2021.100275
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternativesLe Hingrat Q. et al.2021Clinical Microbiology and Infection
27 (5), pp. 789.e1-789.e5
10.1016/j.cmi.2020.11.025
Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author's replyAnnane D. ; Grimaldi-Bensouda L. ; Fremeaux-Bacchic V.2021EClinicalMedicine
35, 100866
10.1016/j.eclinm.2021.100866
Are posterior oropharyngeal saliva specimens an acceptable alternative to nasopharyngeal sampling for the monitoring of sars-cov-2 in primary-care settings?Masse S. et al.2021Viruses
13 (5), 761
10.3390/v13050761
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesPlanas D. et al.2021Nature Medicine
27 (5), pp. 917-924
10.1038/s41591-021-01318-5
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohortTubiana S. et al.2021Journal of Infection
82 (5), pp. 186-230
10.1016/j.jinf.2021.01.026
Arterial abnormalities identified in kidneys transplanted into children during the COVID-19 pandemicBerteloot L. et al.2021American Journal of Transplantation
21 (5), pp. 1937-1943
10.1111/ajt.16464
Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohortDellière S. et al.2021Clinical Microbiology and Infection
27 (5), pp. 790.e1-790.e5
10.1016/j.cmi.2020.12.005
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2McCallum M. et al.2021Cell
184 (9), pp. 2332-2347.e16
10.1016/j.cell.2021.03.028
SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?Sancho-Shimizu V. et al.2021Journal of Experimental Medicine
218 (6), e20210446
10.1084/jem.20210446
Stealth Fluorescence Labeling for Live Microscopy Imaging of mRNA DeliveryBaladi T. et al.2021Journal of the American Chemical Society
143 (14), pp. 5413-5424
10.1021/jacs.1c00014
Fast and efficient purification of SARS-CoV-2 RNA dependent RNA polymerase complex expressed in Escherichia coliMadru C. et al.2021PLoS ONE
16 (4 April), e0250610
10.1371/journal.pone.0250610
Virus eradication and synthetic biology: Changes with sars-cov-2?Tournier J.N. ; Kononchik J.2021Viruses
13 (4), 569
10.3390/v13040569
Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020Sermet-Gaudelus I. et al.2021Eurosurveillance
26 (13), 2001782
10.2807/1560-7917.ES.2021.26.13.2001782
SARS-CoV-2 population-based seroprevalence studies in Europe: A scoping reviewGrant R. et al.2021BMJ Open
11 (4), e045425
10.1136/bmjopen-2020-045425
Outcome of asymptomatic patients with positive SARS-CoV-2 viral RNA reverse transcriptase-PCR undergoing surgery: A matched cohort studyVerliere A. et al.2021European Journal of Anaesthesiology
38 (4), pp. 442-444
10.1097/EJA.0000000000001426
Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumoniade Prost N. et al.2021Journal of Clinical Immunology
41 (3), pp. 536-544
10.1007/s10875-021-00994-9
Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional studyRoederer T. et al.2021The Lancet Public Health
6 (4), pp. e202-e209
10.1016/S2468-2667(21)00001-3
Distinctive Features of Kawasaki Disease Following SARS-CoV-2 Infection: a Controlled Study in Paris, FranceToubiana J. et al.2021Journal of Clinical Immunology
41 (3), pp. 526-535
10.1007/s10875-020-00941-0
The presence of Pneumocystis jirovecii in critically ill patients with COVID-19Alanio A. ; Dellière S. ; Voicu S. ; Bretagne S. ; Mégarbane B.2021Journal of Infection
82 (4), pp. 84-123
10.1016/j.jinf.2020.10.034
Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19Issa H. et al.2021Frontiers in Medicine
8, 620990
10.3389/fmed.2021.620990
SARS-CoV-2 viral dynamics in non-human primatesGonçalves A. et al.2021PLoS Computational Biology
17 (3), e1008785
10.1371/JOURNAL.PCBI.1008785
Genomic characterization and phylogenetic analysis of the first SARS-CoV-2 variants introduced in LebanonFeghali R. et al.2021PeerJ
9, 11015
10.7717/peerj.11015
SARS-CoV-2 variants and ending the COVID-19 pandemicFontanet A. et al.2021The Lancet
397 (10278), pp. 952-954
10.1016/S0140-6736(21)00370-6
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infectionBrouwer P.J.M. et al.2021Cell
184 (5), pp. 1188-1200.e19
10.1016/j.cell.2021.01.035
Maturation and persistence of the anti-SARS-CoV-2 memory B cell responseSokal A. et al.2021Cell
184 (5), pp. 1201-1213.e14
10.1016/j.cell.2021.01.050
Association of Intravenous Immunoglobulins plus Methylprednisolone vs Immunoglobulins Alone with Course of Fever in Multisystem Inflammatory Syndrome in ChildrenOuldali N. et al.2021JAMA - Journal of the American Medical Association
325 (9), pp. 855-864
10.1001/jama.2021.0694
Transmission Routes of Severe Acute Respiratory Syndrome Coronavirus 2 among Healthcare Workers of a French University Hospital in Paris, FranceContejean A. et al.2021Open Forum Infectious Diseases
8 (3)
10.1093/ofid/ofab054
Very little influenza in the WHO European Region during the 2020/21 season, weeks40 2020 to 8 2021Adlhoch C. et al.2021Eurosurveillance
26 (11), pp. 1-8
10.2807/1560-7917.ES.2021.26.11.2100221
A self-assessment web-based app to assess trends of the COVID-19 pandemic in France: Observational studyDenis F. et al.2021Journal of Medical Internet Research
23 (3), e26182
10.2196/26182
Is This a Healthy Scientific Controversy or the "savior" Syndrome at Play? COVID-19 and the Hydroxychloroquine ExampleBoneca I.G.2021Microbial Drug Resistance
27 (3), pp. 279-280
10.1089/mdr.2021.29001.igb
Factors associated with severe SARS-CoV-2 infectionOuldali N. et al.2021Pediatrics
147 (3), e2020023432
10.1542/PEDS.2020-023432
COVID-19 Job Exposure Matrix: From the Mat-O-Covid Design to Its ExecutionFadel M. ; Salomon J. ; Descatha A.2021Journal of occupational and environmental medicine
63 (3), pp. e168
10.1097/JOM.0000000000002148
COVID-19 vaccination for cancer patients: Medical and ethical needSpano J.P. ; Barre-Sinoussi F. ; Kieny M.P. ; Marcelin A.G. ; Blay J.Y.2021Bulletin du Cancer
108 (3), pp. 225-227
10.1016/j.bulcan.2021.02.001
Parallel trends in the transmission of SARS-CoV-2 and retail/recreation and public transport mobility during non-lockdown periodsCazelles B. ; Comiskey C. ; Nguyen-Van-Yen B. ; Champagne C. ; Roche B.2021International Journal of Infectious Diseases
104, pp. 693-695
10.1016/j.ijid.2021.01.067
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazinePlaze M. et al.2021International Journal of Antimicrobial Agents
57 (3), 106274
10.1016/j.ijantimicag.2020.106274
To quarantine, or not to quarantine: A theoretical framework for disease control via contact tracingLunz D. ; Batt G. ; Ruess J.2021Epidemics
34, 100428
10.1016/j.epidem.2020.100428
Immunological and virological profile of children with chilblain-like lesions and SARS-CoV-2Fertitta L. et al.2021Journal of the European Academy of Dermatology and Venereology
35 (3), pp. e164-e167
10.1111/jdv.16972
Biostatistics to better detect fishy findingsTarantola A. ; Gautier L.2021The Lancet Infectious Diseases
21 (3), pp. 316-317
10.1016/S1473-3099(20)30557-0
Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU – A case reportGhelfenstein-Ferreira T. et al.2021Medical Mycology Case Reports
31, pp. 15-18
10.1016/j.mmcr.2020.06.006
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1AWhite K.M. et al.2021Science
371 (6532), pp. 926-931
10.1126/science.abf4058
Covid-19: Keeping schools as safe as possibleFontanet A. ; Grant R. ; Greve-Isdahl M. ; Sridhar D.2021The BMJ
372, n524
10.1136/bmj.n524
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal modelsKu M.W. et al.2021Cell Host and Microbe
29 (2), pp. 236-249.e6
10.1016/j.chom.2020.12.010
The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiomeBrett Finlay B. et al.2021Proceedings of the National Academy of Sciences of the United States of America
118 (6), e2010217118
10.1073/pnas.2010217118
Age-specific mortality and immunity patterns of SARS-CoV-2O’Driscoll M. et al.2021Nature
590 (7844), pp. 140-145
10.1038/s41586-020-2918-0
Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning studyRosado J. et al.2021The Lancet Microbe
2 (2), pp. e60-e69
10.1016/S2666-5247(20)30197-X
Persistent bilateral Tapia syndrome following critical COVID-19Yatim N. ; Bonnet N. ; Wing Tin S.N. ; Cohen Y. ; Degos B.2021Clinical Neurophysiology
132 (2), pp. 505-506
10.1016/j.clinph.2020.12.007
Institut Pasteur International Network's efforts to guide control measures against the coronavirus disease 2019 (COVID-19) epidemic among healthcare workers in AfricaRandremanana R. et al.2021International Journal of Infectious Diseases
103, pp. 525-526
10.1016/j.ijid.2020.12.032
Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma PatientSzwebel T.A. et al.2021Stem Cell Reviews and Reports
17 (1), pp. 296-299
10.1007/s12015-020-10107-5
When Therapeutic IgA Antibodies Might Come of AgeSterlin D. ; Gorochov G.2021Pharmacology
106 (1-2), pp. 9-19
10.1159/000510251
Evaluating the motivation of Red Cross Health volunteers in the COVID-19 pandemic: A mixed-methods study protocolHeyerdahl L.W. et al.2021BMJ Open
11 (1), e042579
10.1136/bmjopen-2020-042579
IgA dominates the early neutralizing antibody response to SARS-CoV-2Sterlin D. et al.2021Science Translational Medicine
13 (577), eabd2223
10.1126/scitranslmed.abd2223
Comparing Dynamics and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 Transmissions among Healthcare Workers of Adult and Pediatric Settings in Central ParisContejean A. et al.2021Clinical Infectious Diseases
72 (2), pp. 257-264
10.1093/cid/ciaa977
Gastrointestinal Symptoms Followed by Shock in a Febrile 7-Year-Old Child during the COVID-19 PandemicAllali S. ; Cohen J.F. ; Brice J. ; Khraiche D. ; Toubiana J.2021Clinical chemistry
67 (1), pp. 54-58
10.1093/clinchem/hvaa279
Correction to: Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection (Journal of Clinical Immunology, (2021), 10.1007/s10875-021-01119-y)Rodero M.P. et al.2021Journal of Clinical Immunology10.1007/s10875-021-01135-y
COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fightAuffray C. et al.2021F1000Research
9, pp. 1-18
10.12688/F1000RESEARCH.26098.1
Use of lentiviral vectors in vaccinationKu M.W. ; Charneau P. ; Majlessi L.2021Expert Review of Vaccines
20 (12), pp. 1571-1586
10.1080/14760584.2021.1988854
Demographic and Clinical Characteristics Associated with Severity, Clinical Outcomes, and Mortality of COVID-19 Infection in GabonIroungou B.A. et al.2021JAMA Network Open
, e2124190
10.1001/jamanetworkopen.2021.24190
Membraneless organelles restructured and built by pandemic viruses: HIV-1 and SARS-CoV-2Scoca V. ; Di Nunzio F.2021Journal of Molecular Cell Biology
13 (4), pp. 259-268
10.1093/jmcb/mjab020
Origin, evolution and global spread of SARS-CoV-2Zhukova A. et al.2021Comptes Rendus - Biologies
344 (1), pp. 57-75
10.5802/CRBIOL.29
Structure-function relations of the sars-cov-2 spike protein and impact of mutations in the variants of concernRey F.2021Comptes Rendus - Biologies
344 (1), pp. 77-110
10.5802/CRBIOL.53
Clinical features and outcomes of COVID-19 patients hospitalized for psychiatric disorders: A French multi-centered prospective observational studyDobre D. et al.2021Psychological Medicine10.1017/S0033291721001537
SARS-CoV-2 infection in schools in a northern French city: A retrospective serological cohort study in an area of high transmission, France, January to April 2020Fontanet A. et al.2021Eurosurveillance
26 (15), pp. 1-12
10.2807/1560-7917.ES.2021.26.15.2001695
Improving care of migrants is key for viral hepatitis elimination in europeKim J.U. ; Ingiliz P. ; Shimakawa Y. ; Lemoine M.2021Bulletin of the World Health Organization
99 (4), pp. 280-286
10.2471/BLT.20.260919
SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiotaSokol H. et al.2021Gut Microbes
13 (1), pp. 1-19
10.1080/19490976.2021.1893113
Addressing vulnerabilities in communities facing infectious disease threats: A need for social science-driven assessmentsOsborne J. et al.2021Journal of Global Health
11, pp. 1-4
10.7189/jogh.11.03003
A Conceptual Discussion about the Basic Reproduction Number of Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare SettingsTemime L. et al.2021Clinical Infectious Diseases
72 (1), pp. 141-143
10.1093/cid/ciaa682
Correction to: IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2 (Journal of Clinical Immunology, (2021), 41, 1, (26-27), 10.1007/s10875-020-00933-0)Lévy R. et al.2021Journal of Clinical Immunology
41 (1), pp. 28
10.1007/s10875-021-00969-w
Impact of the lockdown on the burden of COVID-19 in outpatient care in France, spring 2020Souty C. et al.2021Infectious Diseases
53 (5), pp. 376-381
10.1080/23744235.2021.1880024
Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplificationGarneret P. et al.2021PLoS ONE
16 (1 January), e0243712
10.1371/journal.pone.0243712
IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2Lévy R. et al.2021Journal of Clinical Immunology
41 (1), pp. 26-27
10.1007/s10875-020-00933-0
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in ParisAnna F. et al.2021European Journal of Immunology
51 (1), pp. 180-190
10.1002/eji.202049058
Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemicBaay M. et al.2021Biologicals
69, pp. 76-82
10.1016/j.biologicals.2020.11.003
Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on “Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome” by Quartuccio et al. Joint Bone Spine. 2020;87:191–93Vieira M. et al.2021Joint Bone Spine
88 (1), 105074
10.1016/j.jbspin.2020.09.006
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive SpikeSchoof M. et al.2020Science
370 (6523), pp. 1473-1479
10.1126/science.abe3255
Reconstruction of Transmission Pairs for Novel Coronavirus Disease 2019 (COVID-19) in Mainland China: Estimation of Superspreading Events, Serial Interval, and Hazard of InfectionXu X.K. et al.2020Clinical Infectious Diseases
71 (12), pp. 3163-3167
10.1093/cid/ciaa790
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanismsGordon D.E. et al.2020Science
370 (6521), eabe9403
10.1126/science.abe9403
Association between SARS-CoV-2 infection and Kawasaki-like multisystem inflammatory syndrome: A retrospective matched case–control study, Paris, France, April to May 2020Toubiana J. et al.2020Eurosurveillance
25 (48)
10.2807/1560-7917.ES.2020.25.48.2001813
Impact of mass testing during an epidemic rebound of SARS-CoV-2: A modelling study using the example of FranceBosetti P. et al.2020Eurosurveillance
26 (1)
10.2807/1560-7917.ES.2020.26.1.2001978
Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virusCocozza F. et al.2020Journal of Extracellular Vesicles
10 (2), e12050
10.1002/jev2.12050
The Importance of Biobanking for Response to Pandemics Caused by Emerging Viruses: The European Virus Archive As an Observatory of the Global Response to the Zika Virus and COVID-19 CrisisCoutard B. et al.2020Biopreservation and Biobanking
18 (6), pp. 561-569
10.1089/bio.2020.0119
Optimizing COVID-19 surveillance in long-term care facilities: a modelling studySmith D.R.M. et al.2020BMC Medicine
18 (1), 386
10.1186/s12916-020-01866-6
A comparison of non-magnetic and magnetic beads for measuring IgG antibodies against Plasmodium vivax antigens in a multiplexed bead-based assay using Luminex technology (Bio-Plex 200 or MAGPIX)Mazhari R. et al.2020PLoS ONE
15 (12 December), e0238010
10.1371/journal.pone.0238010
What causes hidradenitis suppurativa ?—15 years afterZouboulis C.C. et al.2020Experimental Dermatology
29 (12), pp. 1154-1170
10.1111/exd.14214
Survival of the Wealthiest?Garfinkel M. ; Sansonetti P.J. ; Pulverer B.2020EMBO Journal
39 (23), e107227
10.15252/embj.2020107227
Anti-infective therapy against SARS-CoV-2: some light at the end of the tunnel?Montravers P. ; Kantor E. ; Gouel-Cheron A.2020Anaesthesia Critical Care and Pain Medicine
39 (6), pp. 695-697
10.1016/j.accpm.2020.10.004
Syncytia formation by SARS-CoV-2-infected cellsBuchrieser J. et al.2020EMBO Journal
39 (23), e106267
10.15252/embj.2020106267
Complement C5 inhibition in patients with COVID-19 - A promising target?de Latour R.P. et al.2020Haematologica
105 (12), pp. 2847-2850
10.3324/haematol.2020.260117
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severityHuang A.T. et al.2020Nature Communications
11 (1), 4704
10.1038/s41467-020-18450-4
Absence of SARS-CoV-2 infection in cats and dogs in close contact with a cluster of COVID-19 patients in a veterinary campusTemmam S. et al.2020One Health
10, 100164
10.1016/j.onehlt.2020.100164
SARS-CoV-2 natural transmission from human to Cat, Belgium, March 2020Garigliany M. et al.2020Emerging Infectious Diseases
26 (12), pp. 3069-3071
10.3201/EID2612.202223
Author Correction: COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms (Scientific Data, (2020), 7, 1, (136), 10.1038/s41597-020-0477-8)Ostaszewski M. et al.2020Scientific Data
7 (1), 247
10.1038/s41597-020-00589-w
COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanismsOstaszewski M. et al.2020Scientific Data
7 (1), 136
10.1038/s41597-020-0477-8
Epidemiological data from the COVID-19 outbreak, real-time case informationXu B. et al.2020Scientific Data
7 (1), 106
10.1038/s41597-020-0448-0
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanismsTortorici M.A. et al.2020Science
370 (6519), pp. 950-957
10.1126/science.abe3354
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyPiccoli L. et al.2020Cell
183 (4), pp. 1024-1042.e21
10.1016/j.cell.2020.09.037
Implementation of a self-triage web application for suspected COVID-19 and its impact on emergency call centers: Observational studyGalmiche S. et al.2020Journal of Medical Internet Research
22 (11), e22924
10.2196/22924
COVID-19 and vaccination: A global disruptionBillon-Denis E. ; Tournier J.N.2020Medecine/Sciences
36 (11), pp. 1034-1037
10.1051/medsci/2020203
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept studyAnnane D. et al.2020EClinicalMedicine
28, 100590
10.1016/j.eclinm.2020.100590
Brief comparative evaluation of six open one-step RT-qPCR mastermixes for the detection of SARS-CoV-2 RNA using a Taqman probeHaddar C. ; Verhoeven P.O. ; Bourlet T. ; Pozzetto B. ; Pillet S.2020Journal of Clinical Virology
132, 104636
10.1016/j.jcv.2020.104636
Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan AfricaLemoine M. et al.2020The Lancet Gastroenterology and Hepatology
5 (11), pp. 966-967
10.1016/S2468-1253(20)30305-8
Clustering and superspreading potential of SARS-CoV-2 infections in Hong KongAdam D.C. et al.2020Nature Medicine
26 (11), pp. 1714-1719
10.1038/s41591-020-1092-0
A review of the main histopathological findings in coronavirus disease 2019Vasquez-Bonilla W.O. et al.2020Human Pathology
105, pp. 74-83
10.1016/j.humpath.2020.07.023
Animal and translational models of SARS-CoV-2 infection and COVID-19Johansen M.D. et al.2020Mucosal Immunology
13 (6), pp. 877-891
10.1038/s41385-020-00340-z
First detection and genome sequencing of SARS-CoV-2 in an infected cat in FranceSailleau C. et al.2020Transboundary and Emerging Diseases
67 (6), pp. 2324-2328
10.1111/tbed.13659
Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patientsSmadja D.M. et al.2020Angiogenesis
23 (4), pp. 611-620
10.1007/s10456-020-09730-0
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19Zhang Q. et al.2020Science
370 (6515), eabd4570
10.1126/science.abd4570
Autoantibodies against type I IFNs in patients with life-threatening COVID-19Bastard P. et al.2020Science
370 (6515), eabd4585
10.1126/science.abd4585
Lockdown impact on COVID-19 epidemics in regions across metropolitan FranceCauchemez S. ; Kiem C.T. ; Paireau J. ; Rolland P. ; Fontanet A.2020The Lancet
396 (10257), pp. 1068-1069
10.1016/S0140-6736(20)32034-1
No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donationCappy P. et al.2020Blood
136 (16), pp. 1888-1891
10.1182/BLOOD.2020008230
COVID-19 herd immunity: where are we?Fontanet A. ; Cauchemez S.2020Nature Reviews Immunology
20 (10), pp. 583-584
10.1038/s41577-020-00451-5
Monitoring approaches for health-care workers during the COVID-19 pandemicBielicki J.A. et al.2020The Lancet Infectious Diseases
20 (10), pp. e261-e267
10.1016/S1473-3099(20)30458-8
Rapid Genomic Characterization of SARS-CoV-2 by Direct Amplicon-Based Sequencing Through Comparison of MinION and Illumina iSeq100TM SystemHourdel V. et al.2020Frontiers in Microbiology
11, 571328
10.3389/fmicb.2020.571328
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primatesMaisonnasse P. et al.2020Nature
585 (7826), pp. 584-587
10.1038/s41586-020-2558-4
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19Silvin A. et al.2020Cell
182 (6), pp. 1401-1418.e18
10.1016/j.cell.2020.08.002
A comprehensive, flexible collection of SARS-CoV-2 coding regionsKim D.K. et al.2020G3: Genes, Genomes, Genetics
10 (9), pp. 3399-3402
10.1534/g3.120.401554
Modeling the inactivation of viruses from the Coronaviridae family in response to temperature and relative humidity in suspensions or on surfacesGuillier L. et al.2020Applied and Environmental Microbiology
86 (18), e01244
10.1128/AEM.01244-20
COVID-19 in Patients on Maintenance Dialysis in the Paris RegionTortonese S. et al.2020Kidney International Reports
5 (9), pp. 1535-1544
10.1016/j.ekir.2020.07.016
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern FranceFafi-Kremer S. et al.2020EBioMedicine
59, 102915
10.1016/j.ebiom.2020.102915
Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysisOuldali N. et al.2020The Lancet Child and Adolescent Health
4 (9), pp. 662-668
10.1016/S2352-4642(20)30175-9
Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A position paperMaillard J.Y. et al.2020American Journal of Infection Control
48 (9), pp. 1090-1099
10.1016/j.ajic.2020.04.011
Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventionsAli S.T. et al.2020Science
369 (6507), pp. 1106-1109
10.1126/science.abc9004
Characterization of accessory genes in coronavirus genomesMichel C.J. ; Mayer C. ; Poch O. ; Thompson J.D.2020Virology Journal
17 (1), 131
10.1186/s12985-020-01402-1
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patientsHadjadj J. et al.2020Science
369 (6504), pp. 718-724
10.1126/science.abc6027
The Global Phosphorylation Landscape of SARS-CoV-2 InfectionBouhaddou M. et al.2020Cell
182 (3), pp. 685-712.e19
10.1016/j.cell.2020.06.034
A race against the clock: Creation of SARS-CoV-2 in the laboratory, a month after its emergence!Iseni F. ; Tournier J.N.2020Medecine/Sciences
36 (8-9), pp. 797-801
10.1051/medsci/2020124
An Old Cytokine against a New VirusPellegrini S. ; Uzé G.2020Journal of Interferon and Cytokine Research
40 (8), pp. 425-428
10.1089/jir.2020.0130
Structural insight into the role of novel SARSCoV-2 E protein: A potential target for vaccine development and other therapeutic strategiesSarkar M. ; Saha S.2020PLoS ONE
15 (8 August), e0237300
10.1371/journal.pone.0237300
Delayed laboratory response to COVID-19 caused by molecular diagnostic contaminationMögling R. et al.2020Emerging Infectious Diseases
26 (8), pp. 1944-1946
10.3201/eid2608.201843
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohortPouletty M. et al.2020Annals of the Rheumatic Diseases
79 (8), pp. 999-1006
10.1136/annrheumdis-2020-217960
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinionVerweij P.E. et al.2020Intensive Care Medicine
46 (8), pp. 1524-1535
10.1007/s00134-020-06091-6
Minimising COVID-19 exposure during tracheal intubation by using a transparent plastic box: A randomised prospective simulation studyClariot S. ; Dumain G. ; Gauci E. ; Langeron O. ; Levesque É.2020Anaesthesia Critical Care and Pain Medicine
39 (4), pp. 461-463
10.1016/j.accpm.2020.06.005
A SARS-CoV-2 protein interaction map reveals targets for drug repurposingGordon D.E. et al.2020Nature
583 (7816), pp. 459-468
10.1038/s41586-020-2286-9
Estimating the burden of SARS-CoV-2 in FranceSalje H. et al.2020Science
369 (6500), pp. 208-211
10.1126/science.abc3517
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibodyPinto D. et al.2020Nature
583 (7815), pp. 290-295
10.1038/s41586-020-2349-y
Interplay between SARS-CoV-2 and the type I interferon responseRibero M.S. ; Jouvenet N. ; Dreux M. ; Nisole S.2020PLoS Pathogens
16 (7), e1008737
10.1371/journal.ppat.1008737
Knowledge, attitude, and perceptions towards the 2019 Coronavirus Pandemic: A bi-national survey in AfricaHager E. et al.2020PLoS ONE
15 (7 July), e0236918
10.1371/journal.pone.0236918
Planetary health: young academics ask universities to actWabnitz K.J. et al.2020The Lancet Planetary Health
4 (7), pp. e257-e258
10.1016/S2542-5196(20)30142-X
SARS-CoV-2: Virology, epidemiology, immunology and vaccine developmentBaay M. et al.2020Biologicals
66, pp. 35-40
10.1016/j.biologicals.2020.06.005
A hybrid approach to tracheostomy in COVID-19 patients ensuring staff safetyTanaka L. et al.2020British Journal of Surgery
107 (8), pp. e253-e254
10.1002/bjs.11705
Working from home in the time of COVID-19: How to best preserve occupational health?Bouziri H. et al.2020Occupational and Environmental Medicine
77 (7), pp. 509-510
10.1136/oemed-2020-106599
Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 PatientsBost P. et al.2020Cell
181 (7), pp. 1475-1488.e12
10.1016/j.cell.2020.05.006
Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliableMavian C. et al.2020Proceedings of the National Academy of Sciences of the United States of America
117 (23), pp. 12522-12523
10.1073/pnas.2007295117
Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational studyToubiana J. et al.2020BMJ (Clinical research ed.)
369, pp. m2094
10.1136/bmj.m2094
Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery studyPlaze M. et al.2020Encephale
46 (3), pp. S35-S39
10.1016/j.encep.2020.04.010
French psychiatry and the novelty of the COVID-19 crisisMasson M. ; Gaillard R.2020Encephale
46 (3), pp. S1-S2
10.1016/j.encep.2020.06.001
Epidemiological Observations on the Association between Anosmia and COVID-19 Infection: Analysis of Data from a Self-Assessment Web ApplicationDenis F. et al.2020Journal of Medical Internet Research
22 (6), e19855
10.2196/19855
Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19Alanio A. ; Dellière S. ; Fodil S. ; Bretagne S. ; Mégarbane B.2020The Lancet Respiratory Medicine
8 (6), pp. e48-e49
10.1016/S2213-2600(20)30237-X
Repurposing chlorpromazine to treat COVID-19: The reCoVery studyPlaze M. et al.2020Encephale
46 (3), pp. 169-172
10.1016/j.encep.2020.05.006
Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseasesvon Lilienfeld-Toal M. et al.2020Leukemia
34 (6), pp. 1487-1494
10.1038/s41375-020-0832-y
Preliminary observations of anaesthesia ventilators use for prolonged mechanical ventilation in intensive care unit patients during the COVID-19 pandemicGouel-Cheron A. ; Couffignal C. ; Elmaleh Y. ; Kantor E. ; Montravers P.2020Anaesthesia Critical Care and Pain Medicine
39 (3), pp. 371-372
10.1016/j.accpm.2020.04.009
Invasive fungal diseases during COVID-19: We should be preparedGangneux J.P. ; Bougnoux M.E. ; Dannaoui E. ; Cornet M. ; Zahar J.R.2020Journal de Mycologie Medicale
30 (2), 100971
10.1016/j.mycmed.2020.100971
Clinical and virological data of the first cases of COVID-19 in Europe: a case seriesLescure F.X. et al.2020The Lancet Infectious Diseases
20 (6), pp. 697-706
10.1016/S1473-3099(20)30200-0
Serial interval of COVID-19 among publicly reported confirmed casesDu Z. et al.2020Emerging Infectious Diseases
26 (6), pp. 1341-1343
10.3201/EID2606.200357
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 PatientsBonam S.R. ; Kaveri S.V. ; Sakuntabhai A. ; Gilardin L. ; Bayry J.2020Cell Reports Medicine
1 (2), 100016
10.1016/j.xcrm.2020.100016
COVID-19, chronicle of an expected pandemicSansonetti P.J.2020EMBO Molecular Medicine
12 (5), e12463
10.15252/emmm.202012463
Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assaysCrawford K.H.D. et al.2020Viruses
12 (5), 513
10.3390/v12050513
The effect of human mobility and control measures on the COVID-19 epidemic in ChinaKraemer M.U.G. et al.2020Science
368 (6490), pp. 493-497
10.1126/science.abb4218
Chloroquine and COVID-19, where do we stand?Lecuit M.2020Medecine et Maladies Infectieuses
50 (3), pp. 229-230
10.1016/j.medmal.2020.03.004
Risk for transportation of coronavirus disease from Wuhan to other cities in ChinaDu Z. et al.2020Emerging Infectious Diseases
26 (5), pp. 1049-1052
10.3201/eid2605.200146
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike GlycoproteinWalls A.C. et al.2020Cell
181 (2), pp. 281-292.e6
10.1016/j.cell.2020.02.058
Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020Boëlle P.Y. et al.2020Eurosurveillance
25 (14), 2000326
10.2807/1560-7917.ES.2020.25.14.2000326
Facing challenges with the novel coronavirus SARS-CoV-2 outbreakvan der Werf S. ; Peltekian C.2020Virologie (Montrouge, France)
24 (S1), pp. e12-e15
10.1684/vir.2020.0826
Coronavirus outbreak: the role of companies in preparedness and responsesFadel M. ; Salomon J. ; Descatha A.2020The Lancet Public Health
5 (4), pp. e193
10.1016/S2468-2667(20)30051-7
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020Spiteri G. et al.2020Eurosurveillance
25 (9), 2000178
10.2807/1560-7917.ES.2020.25.9.2000178
First cases of coronavirus disease 2019 (COVID-19) in France: Surveillance, investigations and control measures, January 2020Stoecklin S.B. et al.2020Eurosurveillance
25 (6), 2000094
10.2807/1560-7917.ES.2020.25.6.2000094
Highly performing point-of-care molecular testing for sars-cov-2 with RNA extraction and isothermal amplificaitonCoz E. et al.2020MicroTAS 2020 - 24th International Conference on Miniaturized Systems for Chemistry and Life Sciences
, pp. 1232-1233
Rapid detection of COVID-19 by serological methods and the evaluation of diagnostic efficacy of IgM and IgGHuang S. et al.2020Clinical Laboratory
66 (11), pp. 2327-2333
10.7754/Clin.Lab.2020.200617
Pandemic legion history more complex than previously thoughtTournier J.N.2020mBio
11 (5), e02377-20
10.1128/mBio.02377-20
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populationsGrzelak L. et al.2020Science Translational Medicine
12 (559), eabc3103
10.1126/SCITRANSLMED.ABC3103
Randomized controlled study evaluating efficiency of low intensity transcranial direct current stimulation (TDCS) for dyspnea relief in mechanically ventilated COVID-19 patients in ICU: The tDCS-DYSP-COVID protocolAzabou E. et al.2020Frontiers in Medicine
7, 372
10.3389/fmed.2020.00372
Introductions and early spread of SARS-CoV-2 in france, 24 january to 23 march 2020Gámbaro F. et al.2020Eurosurveillance
25 (26)
10.2807/1560-7917.ES.2020.25.26.2001200
A nicotinic hypothesis for Covid-19 with preventive and therapeutic implicationsChangeux J.P. ; Amoura Z. ; Rey F.A. ; Miyara M.2020Comptes Rendus - Biologies
343 (1), pp. 33-39
10.5802/crbiol.8


Abonnez-vous à la newsletter

Retour en haut